The elevated levels of sPD-L1 and sPD1 in metastatic melanoma as respect to healthy have also been confirmed by Ugurel [17], who demonstrated that both immune checkpoints were present in the serum at higher concentrations before immunotherapy in non-responders. The gene discussed is HOXD13; the disease is metastatic melanoma.